{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:27:37Z","timestamp":1787308057948,"version":"build-2736575974"},"reference-count":46,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.16.04187","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:01:48Z","timestamp":1787306508000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis"],"prefix":"10.7189","volume":"16","author":[{"given":"Soo Hyeon","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea"},{"name":"Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Rho","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Institute of Integrated Pharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangyoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Terre Haute, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooyoung","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, Republic of Korea"},{"name":"Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Jin","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea"},{"name":"Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul, Republic of Korea"},{"name":"College of Pharmacy and Institute of Integrated Pharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"key-10.7189\/jogh.16.04187-202608201905-R1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson\u2019s disease.","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R3","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021.","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R4","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.lanepe.2024.100870","article-title":"The impact of psychiatric comorbidity on Parkinson\u2019s disease outcomes: a systematic review and meta-analysis.","volume":"39","author":"Burchill","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee.","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R6","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.dscb.2024.100158","article-title":"The association between type 2 diabetes mellitus and Parkinson\u2019s disease; a systematic review and meta-analysis.","volume":"15","author":"Bantounou","year":"2024","journal-title":"Brain Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3233\/JPD-230104","article-title":"Diabetes and Parkinson\u2019s disease: Understanding shared molecular mechanisms.","volume":"14","author":"K\u00f6nig","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.freeradbiomed.2012.11.014","article-title":"Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.","volume":"62","author":"Yan","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R9","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S1353-8020(11)70008-6","article-title":"Misfolded \u03b1-synuclein and Toll-like receptors: therapeutic targets for Parkinson\u2019s disease.","volume":"18","author":"B\u00e9raud","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration.","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fnins.2019.00868","article-title":"The relevance of insulin action in the dopaminergic system.","volume":"13","author":"Fiory","year":"2019","journal-title":"Front Neurosci"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.amepre.2024.04.014","article-title":"Risk of dementia and Alzheimer\u2019s disease associated with antidiabetics: A Bayesian network meta-analysis.","volume":"67","author":"Sunwoo","year":"2024","journal-title":"Am J Prev Med"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R13","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1002\/brx2.52","article-title":"Prospects of antidiabetic drugs in the treatment of neurodegernative disease.","volume":"2","author":"Hu","year":"2024","journal-title":"Brain-X"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R14","doi-asserted-by":"publisher","first-page":"107220","DOI":"10.1016\/j.parkreldis.2024.107220","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease: An updated meta-analysis.","volume":"130","author":"Albuquerque","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R16","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R17","unstructured":"Cochrane. Chapter 11: Undertaking network meta-analyses. 2019. Available: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-11. Accessed 5 August 2025."},{"key":"key-10.7189\/jogh.16.04187-202608201905-R18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/13543784.2023.2263354","article-title":"SGLT2 inhibitors: an evidence-based update on cardiovascular implications.","volume":"32","author":"Forzano","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review.","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R20","doi-asserted-by":"publisher","first-page":"e209805","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes.","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R21","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.2337\/dc25-SREV","article-title":"Summary of revisions: Standards of care in diabetes-2025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis.","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/mds.27128","article-title":"Glitazone use associated with reduced risk of Parkinson\u2019s disease.","volume":"32","author":"Brakedal","year":"2017","journal-title":"Mov Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R24","doi-asserted-by":"publisher","first-page":"747620","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: A propensity score-matched population-based study with competing risk analysis.","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1177\/1877718X251359391","article-title":"SGLT2 inhibitors vs. metformin for Parkinson\u2019s disease risk reduction in type 2 diabetes.","volume":"15","author":"Sun","year":"2025","journal-title":"J Parkinsons Dis"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R26","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1111\/dom.15943","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.","volume":"26","author":"Guo","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R27","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-like peptide-1 receptor agonists and risk of Parkinson\u2019s disease in patients with type 2 diabetes: A population-based cohort study.","volume":"39","author":"Tang","year":"2024","journal-title":"Mov Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R28","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/aje\/kwv109","article-title":"Thiazolidinediones and Parkinson disease: A cohort study.","volume":"182","author":"Connolly","year":"2015","journal-title":"Am J Epidemiol"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R29","doi-asserted-by":"publisher","first-page":"11994","DOI":"10.18632\/aging.206074","article-title":"Association between dipeptidyl peptidase-4 inhibitor use and risk of Parkinson\u2019s disease among patients with diabetes mellitus: a retrospective cohort study.","volume":"16","author":"Huang","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41531-022-00406-8","article-title":"Thiazolidinedione use and risk of Parkinson\u2019s disease in patients with type 2 diabetes mellitus.","volume":"8","author":"Zhao","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R31","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes.","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R32","doi-asserted-by":"publisher","first-page":"107439","DOI":"10.1016\/j.phrs.2024.107439","article-title":"Type 2 diabetes mellitus and neurodegenerative disorders: The mitochondrial connection.","volume":"209","author":"Baduini","year":"2024","journal-title":"Pharmacol Res"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment.","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/cells14100710","article-title":"Exploring risk and protective factors in Parkinson\u2019s disease.","volume":"14","author":"Beheshti","year":"2025","journal-title":"Cells"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R35","doi-asserted-by":"publisher","first-page":"107026","DOI":"10.1016\/j.parkreldis.2024.107026","article-title":"Update: Protective and risk factors for Parkinson disease.","volume":"125","author":"Grotewold","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12868-024-00875-y","article-title":"Cardiovascular history and risk of idiopathic Parkinson\u2019s disease: a cross-sectional observational study.","volume":"25","author":"Acharya","year":"2024","journal-title":"BMC Neurosci"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.119.044948","article-title":"Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: A nationwide, population-based cohort study.","volume":"141","author":"Park","year":"2020","journal-title":"Circulation"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R38","doi-asserted-by":"publisher","first-page":"21928","DOI":"10.1038\/s41598-024-72549-y","article-title":"Cardiovascular outcomes in Parkinson\u2019s disease patients from a retrospective cohort study.","volume":"14","author":"Lim","year":"2024","journal-title":"Sci Rep"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.14802\/jmd.16001","article-title":"Cardiovascular autonomic dysfunction in mild and advanced Parkinson\u2019s disease.","volume":"9","author":"Kim","year":"2016","journal-title":"J Mov Disord"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R40","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s13311-020-00897-4","article-title":"Autonomic Dysfunction in Parkinson\u2019s Disease.","volume":"17","author":"Pfeiffer","year":"2020","journal-title":"Neurotherapeutics"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R41","doi-asserted-by":"publisher","first-page":"113537","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: A large-scale propensity-matched cohort study.","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R42","doi-asserted-by":"publisher","first-page":"e047993","DOI":"10.1136\/bmjopen-2020-047993","article-title":"Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3\u2032 study.","volume":"11","author":"Vijiaratnam","year":"2021","journal-title":"BMJ Open"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R43","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1186\/s12889-024-19709-x","article-title":"Association between kidney function and Parkinson\u2019s disease risk: a prospective study from the UK Biobank.","volume":"24","author":"Peng","year":"2024","journal-title":"BMC Public Health"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R44","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.12771\/emj.2024.e17","article-title":"Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review.","volume":"47","author":"Joo","year":"2024","journal-title":"Ewha Med J"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12883-024-03820-y","article-title":"Association between metabolic syndrome and the risk of Parkinson\u2019s disease: a meta-analysis.","volume":"24","author":"Zhong","year":"2024","journal-title":"BMC Neurol"},{"key":"key-10.7189\/jogh.16.04187-202608201905-R46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1017\/S1041610211002511","article-title":"Cognitive impairment and vitamin B12: a review.","volume":"24","author":"Moore","year":"2012","journal-title":"Int Psychogeriatr"}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"https:\/\/jogh.org\/2026\/jogh-16-04187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:01:50Z","timestamp":1787306510000},"score":1,"resource":{"primary":{"URL":"https:\/\/jogh.org\/2026\/jogh-16-04187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7189\/jogh.16.04187","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"04187"}}